Table 3.
Five-year budget impact
| Strategy and treatments | Scenario analysis | Base case | ||
|---|---|---|---|---|
| Excluding FU costs in 2022–2026 of patients who started between 2018–2021 (in CHF) | Including FU costs in 2022–2026 of patients who started between 2018–2021* (in CHF) |
Budget increase | % Budget increase | |
| No nivo+ipi | 110,944,118 | 127,129,866 | Reference | Reference |
| Swissmedic label | 149,294,663 | 165,480,411 | 38,350,545 | 30% |
| Nivo+ipi targeting all patients with unresectable MPM | 167,985,030 | 184,170,779 | 57,040,913 | 45% |
Beva bevacizumab, BIA budget impact analysis, carbo carboplatin, CHF Swiss Francs, FU follow-up, ipi ipilimumab, MPM malignant pleural mesothelioma, nivo nivolumab, pem pemetrexed
*Before 2022, patients had only started on pem+carbo (50% of patients) and pem+carbo+beva (50% of patients) and continued their original treatment during the BIA time horizon